Novartis and Bristol Myers Squibb have both halted autoimmune CAR-T development after immune-related adverse events in early testing, according to the report. The news follows safety scrutiny that is now forcing pause-and-review decisions across multiple CAR-T programs rather than isolated protocol amendments. The companies’ actions point to heightened attention on autoimmune indications, where immunologic risk may differ from oncology settings. Any restart conditions will likely require additional mechanistic review, refined monitoring, and strengthened risk mitigation plans for recruitment and dosing. Biotech stakeholders will watch whether these pauses trigger broader recalibration of dose intensity, patient selection, or toxicity management standards across the CAR-T sector.